The participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except =< grade 2 alopecia, neuropathy, and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5) grade =< 1 (except alopecia) at the time of enrollmentXx_NEWLINE_xXNervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [v]4) resulting from prior therapy must be =< grade 2Xx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or baseline, with the exception of alopecia)Xx_NEWLINE_xXNervous system disorders (Common Terminology Criteria for Adverse Events version 4 [CTCAE v4]) resulting from prior therapy must be =< grade 2Xx_NEWLINE_xXNervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) resulting from prior therapy must be =< grade 2, with the exception of decreased tendon reflex (DTR); any grade of DTR is eligibleXx_NEWLINE_xXPatients with active >= Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4 grade 2 neuropathy are ineligibleXx_NEWLINE_xXSTEP I: Patients must not have grade 2 or higher peripheral neuropathy by Common Terminology Criteria for Adverse Events (CTCAE) 4.0Xx_NEWLINE_xXPatients must have completed prior chemotherapy, immunotherapy, or radiation therapy at least 14 days prior to step 2 randomization and all toxicity must be resolved to Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0 grade 1 (with the exception of CTCAE v4.0 grade 2 neuropathy) prior to step 2 randomizationXx_NEWLINE_xXPersistent toxicities (>= Common Terminology Criteria for Adverse Events [CTCAE] grade 2) caused by previous cancer therapy, excluding alopecia and CTCAE grade 2 peripheral neuropathyXx_NEWLINE_xXRecovered from adverse events to grade 1 or less toxicity according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0) due to agents administered previously\r\n* NOTE: Chemotherapy-induced alopecia and grade 2 neuropathy are acceptableXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/mm^3 , equivalent to Common Toxicity Criteria (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 3.0) grade 1Xx_NEWLINE_xXNo unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2, prior platinum-therapy–related neuropathyXx_NEWLINE_xXSymptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.0) in patients with no prior oxaliplatin therapyXx_NEWLINE_xXPatients may have received prior surgery; all adverse events associated with prior surgery must have resolved to =< grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] 4.0) prior to registrationXx_NEWLINE_xXPatients requiring hearing aids or reporting hearing loss must have audiogram performed within 28 days prior to step 1 registration; if audiogram is performed, patient must not have hearing impairment >= Common Terminology Criteria for Adverse events (CTCAE) grade 2Xx_NEWLINE_xXPatients must not have Common Terminology Criteria for Adverse Events (CTCAE) >= grade 2 neuropathy (cranial, motor or sensory) within 14 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1,500/mcl, equivalent to Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xXNervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4) resulting from prior therapy must be =< grade 2Xx_NEWLINE_xXNervous system disorders (by Common Terminology Criteria for Adverse Events version 5.0 [CTCAE V 5.0]) resulting from prior therapy must be =< grade 2, with the exception of decreased tendon reflex (DTR); any grade of DTR is eligibleXx_NEWLINE_xXPatient has Common Toxicity Criteria for Adverse Effects (CTCAE) v 4.0 grade ? 2 hemorrhageXx_NEWLINE_xXAll prior anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed above) must be =< grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03, 2009) at the time of starting treatmentXx_NEWLINE_xXSymptomatic peripheral neuropathy >= grade 2 Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 (for participants receiving docetaxel only)Xx_NEWLINE_xXPersistent toxicities (>= Common Terminology Criteria for Adverse Events [CTCAE] grade 2) caused by previous cancer therapy, excluding alopeciaXx_NEWLINE_xXPeripheral sensory neuropathy >/= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2Xx_NEWLINE_xXPre-existing, clinically significant peripheral neuropathy, defined as Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher neurosensory or neuromotor toxicity, regardless of etiologyXx_NEWLINE_xXWith the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatmentXx_NEWLINE_xXPresence of grade >= 2 Common Terminology Criteria for Adverse Events (CTCAE) toxicity (CTCAE grade 2 peripheral neuropathy and ototoxicity and any grade alopecia are allowed)Xx_NEWLINE_xXClinically active infection as judged by the site investigator (>= grade 2 by Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4)Xx_NEWLINE_xXRecovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less toxicity from other agents with exception of alopecia and fatigueXx_NEWLINE_xXPatients who have not recovered to < Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicities related to prior therapy are ineligibleXx_NEWLINE_xXParticipant has unresolved, clinically significant toxicities from prior anticancer therapy, defined as greater than Grade 1 on Common Terminology for adverse events.Xx_NEWLINE_xXHistory of high grade (Common Terminology Criteria for Adverse Events [CTCAE] >= grade 3) immune mediated adverse event from prior cancer immunotherapyXx_NEWLINE_xXHas had chemotherapy, radiation or biological cancer therapy within 4 weeks prior to the first dose of study drug, or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 or 1 from the AEs due to cancer therapeutics administered more than 4 weeks earlier (this includes participants with previous immunomodulatory therapy with residual immune-related [ir]AEs).Xx_NEWLINE_xXPrior treatment-related adverse events (AEs) must be =< grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] v4.0), except alopecia, at time of initiating study drugXx_NEWLINE_xXPrior locoregional liver directed therapy is allowed as long as treatment was at least 6 weeks prior to study registration, and clear progression is demonstrated by RECIST v1.1 criteria; subject must have recovered from the acute toxic effects (=< grade 1 Common Terminology Criteria for Adverse Events [CTCAE] v4) of previous anti-cancer treatment prior to study enrollment; the only exception is that grade 2 neuropathy is permittedXx_NEWLINE_xXThyroid function abnormality ? Common Toxicity Criteria for Adverse Effects (CTCAE) Grade 2.Xx_NEWLINE_xXPatients with gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade >= 3 within 30 days prior to study entryXx_NEWLINE_xXFailure to recover (to Common Terminology Criteria for Adverse Events [CTCAE Version 4.0] Grade 0 or Grade 1) from acute non-hematologic toxicity (except alopecia or Grade 2 or lower neuropathy), due to previous therapy, prior to Screening.Xx_NEWLINE_xXRecovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v).4.0 from toxicities related to any prior treatments, unless adverse events (AEs) are clinically nonsignificant and/or stable on supportive therapyXx_NEWLINE_xXAll prior anti-cancer treatment-related toxicities (except alopecia and laboratory values) must be =< grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.0) at the time of randomizationXx_NEWLINE_xXAny unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatmentXx_NEWLINE_xXParticipant has unresolved toxicities from most recent prior anti-cancer therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE v 4.03) grade 2 or higher clinically significant toxicity (excluding alopecia).Xx_NEWLINE_xXToxicities of prior therapy must be resolved to grade 1 or less as per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 with the exception of alopecia and grade 2, prior platinum-therapy related neuropathyXx_NEWLINE_xXPHASE II INCLUSION CRITERIA: Toxicities of prior therapy must be resolved to grade 1 or less as per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 with the exception of alopecia and grade 2, prior platinum-therapy related neuropathyXx_NEWLINE_xXRecovery from all prior surgical or adjuvant treatment-related toxicities, to baseline status, or a Common Terminology Criteria for Adverse Events (CTCAE) grade of 0 or 1, except for toxicities not considered a safety risk, such as alopecia; post-surgical pain will not be considered a basis for exclusionXx_NEWLINE_xXAny unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatmentXx_NEWLINE_xXParticipants who have not recovered to =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or baseline from toxicity as a result of previous cancer treatment prior to entering the study (with the exception of alopecia and peripheral neuropathy which can be =< grade 2)Xx_NEWLINE_xXParticipants who have had chemotherapy, biologic therapy, or investigational therapy within 21 days (including bevizumab) or radiotherapy within 7 days prior to entering the study or those who have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 or baseline from adverse events due to agents administeredXx_NEWLINE_xXRecovered from adverse events (to grade 1 or less toxicity according to Common Terminology Criteria for Adverse Events [CTCAE] 4.0) due to agents administered previously; NOTE: chemotherapy-induced alopecia and grade 2 neuropathy are acceptableXx_NEWLINE_xXLess than 3 days from prior treatment with EGFR TKI; patients with adverse events related to prior EGFR TKI must recover to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 to be eligibleXx_NEWLINE_xXThe participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXNeurologic function: neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xXAny unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE), Grade 1, at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXPrior systemic treatment is allowed, but toxicities of prior therapy must be resolved to grade 1 or less as per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03Xx_NEWLINE_xXAny toxicity due to prior therapy that has not been resolved to less than Grade 2 severity by Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03 or higher) criteriaXx_NEWLINE_xXParticipant has > Common Terminology Criteria for Adverse Events (CTCAE) grade 1 limb edema (5 - 10% inter-limb discrepancy in volume or circumference at point of greatest visible difference; swelling or obscuration of anatomic architecture on close inspection)Xx_NEWLINE_xXAll previous therapies for cancer, including radiotherapy, major surgery and investigational therapies discontinued for ? 14 days (? 28 days for mitomycin C or nitrosoureas) before study entry, and all acute effects of any prior therapy resolved to baseline severity or Grade ? 1 Common Terminology Criteria for Adverse Events (CTCAE v4.03), except alopecia or parameters defined in this eligibility list.Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXHas pre-existing peripheral neuropathy that is ? Grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) version 4 criteria.Xx_NEWLINE_xXMust have received prior therapy with a MET inhibitor; patients must have recovered from all toxicities related to prior anticancer therapies to grade =< 1 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.0); patients with any grade of alopecia are allowed to enter the studyXx_NEWLINE_xXRecovery from all adverse events (AEs) of previous anti-cancer therapies, including surgery, chemotherapy and radiotherapy, to baseline or to Common Terminology Criteria for Adverse Events (CTCAE) grade =< 1, except for alopeciaXx_NEWLINE_xXPatients must be recovered from any toxicity related to prior anti-neoplastic therapy (to grade < 1); patients with Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or less sensory neuropathy or any grade alopecia are eligibleXx_NEWLINE_xXFor subjects with muscle invasive disease: not suitable neoadjuvant cisplatin­based chemotherapy as determined by the following:\r\n* Creatinine clearance less than 60 ml/min\r\n* Common Terminology Criteria for Adverse Events (CTCAE) grade (gr) >= 2 hearing loss\r\n* CTCAE gr >= 2 neuropathyXx_NEWLINE_xXLack of recovery of prior adverse events due to prior cancer therapy to grade =< 1 (NCI Common Terminology Criteria for Adverse Events [CTCAE]; except alopecia); electrolyte abnormalities that are corrected with supplementation will be eligible; patients with platinum-related grade 2 or greater hypomagnesemia (on replacement) will be eligible; stable persistent grade 2 peripheral neuropathy may be allowed as determined on a case-by-case basis at the discretion of the principal investigator (PI)Xx_NEWLINE_xXHave any reported baseline lab values with a grade 3 or 4 toxicity as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0Xx_NEWLINE_xXThe subject has not recovered to baseline, Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies for RCC or to a level permitted under other sections of the eligibility criteria except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXSubjects must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXActive inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as >= Common Toxicity Criteria [CTC] grade 2 [Common Terminology Criteria for Adverse Events (CTCAE) version 4.0])Xx_NEWLINE_xXRecovery from acute toxicity of prior treatment for RCC (to =< grade 1 the active version of Common Terminology Criteria for Adverse Events [CTCAE] or to a level permitted under other sections of inclusion/exclusion criteria)Xx_NEWLINE_xXPatients with persistent toxicities (>= Common Terminology Criteria for Adverse Events [CTCAE] grade 2) with the exception of alopecia, caused by previous cancer therapyXx_NEWLINE_xXPatients who have received palliative radiotherapy within 2 weeks of study entry and have not recovered to grade 1 or baseline from associated toxicities. Note: Patients may receive palliative radiation once enrolled on study. The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies, including surgery, except alopecia and other non-clinically significant adverse events (AEs).Xx_NEWLINE_xXPersistent prior therapy-related toxicities greater than grade 2 according to Common Toxicity Criteria for Adverse Events (CTCAE) v4.03, except for peripheral neuropathy, alopecia, or vitiligo prior to enrollment.Xx_NEWLINE_xXSubjects must have progressed despite at least 1 prior line of treatment for metastatic and/or unresectable urothelial cancer. However, cisplatin-ineligible (defined by a calculated creatinine clearance of >= 40 but < 60 mL/min OR Common Terminology Criteria for Adverse Events [CTCAE] version [v]4 grade >= 2 audiometric hearing loss OR CTCAE v4 grade >= 2 peripheral neuropathy OR ECOG performance status [PS] = 2), chemotherapy-naive subjects are also eligibleXx_NEWLINE_xXProhibited anti-NSCLC therapies and not having recovered from related AEs to Common Terminology Criteria for Adverse Events (CTCAE) Grade ?1Xx_NEWLINE_xXAny unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 (with the exception of alopecia grade 2) at the time of starting study treatmentXx_NEWLINE_xXRecovery to baseline or grade =< 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 from toxicities related to any prior treatments, unless adverse events (AEs) are clinically nonsignificant and/or stable on supportive therapyXx_NEWLINE_xXHas known gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade > 3 within 6 months of start of study drugXx_NEWLINE_xXSTUDY TREATMENT: Peripheral neuropathy less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1.Xx_NEWLINE_xXUnresolved toxicities from prior anti-tumor therapy (defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade 1, or to levels dictated in the eligibility criteria) with the exception of alopecia or toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 28 days] which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and AmgenXx_NEWLINE_xXPresence of ? Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicity due to prior cancer therapy (except alopecia, peripheral neuropathy which are excluded if ? CTCAE grade 3)Xx_NEWLINE_xXProteinuria < Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greaterXx_NEWLINE_xXToxicities related to prior anticancer treatment (except alopecia) that have not resolved to =< grade 1 according to common terminology criteria for adverse events (CTCAE version [V]4.0) before registration or prior to start of therapyXx_NEWLINE_xXPatients with peripheral neuropathy > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXUnresolved toxicity higher than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 attributed to any prior therapy or procedure, excluding alopeciaXx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXIneligible to receive cisplatin by meeting one or more of the following criteria\r\n* Creatinine clearance of < 50 mL/min\r\n* Hearing loss of 25 dB at two contiguous frequencies\r\n* Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v4) grade 2 or higher peripheral neuropathy\r\n* New York Heart Association class III or IV heart failure\r\n* ECOG performance status 2 or higherXx_NEWLINE_xXSerum sodium, potassium, and calcium levels equivalent to grade 1 adverse event (AE) values as defined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0Xx_NEWLINE_xXSubjects with >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicity (except alopecia) due to prior cancer therapy.Xx_NEWLINE_xXResolved acute effects of any prior therapy to baseline severity or grade =< 2 Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03 except for adverse events (AEs) not constituting a safety risk by investigator judgmentXx_NEWLINE_xXAbsolute neutrophil count ? 1,500 cells/uL equivalent to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03) grade 1Xx_NEWLINE_xXPlatelets ? 100,000/uL equivalent to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03) grade 1Xx_NEWLINE_xXPersisting toxicity related to prior therapy (Common Terminology Criteria for Adverse Events [CTCAE] > grade 1); however, alopecia, sensory neuropathy =< grade 2, or other =< grade 2 not constituting a safety risk based on the investigator’s judgment are acceptableXx_NEWLINE_xXPersistent toxicities (>= common terminology criteria for adverse events grade 2) with the exception of alopecia, caused by previous cancer therapy.Xx_NEWLINE_xXAny unresolved toxicity NCI Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria\r\n* Subjects with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the principal investigator\r\n* Subjects with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the principal investigatorXx_NEWLINE_xXSubject has recovered from clinically significant acute treatment related toxicities from all prior therapies. Recovery is defined as a toxicity Grade ? 2 (common terminology criteria for adverse events [CTCAE] v. 4.03).Xx_NEWLINE_xXUnresolved diarrhea >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or a medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease)Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xXAny unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 from previous anti-cancer therapy; exceptions include hearing loss, peripheral neuropathy, and alopeciaXx_NEWLINE_xXThe subject has recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v.)4.03 from toxicities related to any prior treatments, unless adverse event (AE)(s) are clinically nonsignificant and/or stable on supportive therapyXx_NEWLINE_xXRecovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v.)4.03 from toxicities related to any prior treatments, unless adverse events (AE[s]) are clinically non-significant and/or stable on supportive therapyXx_NEWLINE_xXAny unresolved toxicity NCI Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteriaXx_NEWLINE_xXAny unresolved toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade >= 2) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy).Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 4.03) =< grade 1 at the time of screening (except alopecia)Xx_NEWLINE_xXAny unresolved chronic toxicity >= grade 2 from previous anticancer therapy (except alopecia and anemia), according to Common Terminology Criteria for Adverse Events version (v)4.0 (CTCAE)Xx_NEWLINE_xXRecovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 from toxicities related to any prior treatments, unless adverse events (AE[s]) are clinically non-significant and/or stable on supportive therapyXx_NEWLINE_xXAny immunotherapy-related adverse events Common Terminology Criteria for Adverse Events (CTCAE) > grade 1 at the time of registrationXx_NEWLINE_xXAny unresolved toxicity (? Common Terminology Criteria for Adverse Events [CTCAE] grade 2) from previous anti-cancer therapy. NOTE: Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)Xx_NEWLINE_xXMust have completed prior chemotherapy, immunotherapy, or radiation therapy at least 14 days prior to start of treatment and all toxicity must be resolved to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 1 (with the exception of CTCAE v4.0 grade 2 neuropathy) prior to start of treatmentXx_NEWLINE_xXCommon Terminology Criteria for Adverse Events (CTCAE) grade =< 1 dyspnea and oxygen saturation (SaO2) >= 92% on room airXx_NEWLINE_xXThe subjects who have not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from related toxicity to all prior therapies will be excluded; patients with non-serious adverse events such as alopecia, fatigue, weakness, loss of appetite and nausea that are non-significant will not be excludedXx_NEWLINE_xXPrevious treatment-associated clinically significant toxicities resolved to Common Terminology Criteria for Adverse Events (CTCAE) grade =< 1 (except alopecia) or baselineXx_NEWLINE_xXResolution of all acute toxic effects of prior chemotherapy, immunotherapy, radiotherapy or surgical procedures to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03); exception to this criterion: patients with any grade of alopecia are allowed to enter the treatmentXx_NEWLINE_xXThe patient has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from adverse event at time of enrollment due to cancer therapy administered more than 28 days prior to enrollmentXx_NEWLINE_xXAny unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade 2) from previous anti-cancer therapyXx_NEWLINE_xXNo Common Terminology Criteria for Adverse Events (CTCAE) v4 grade > 2 neuropathyXx_NEWLINE_xXHave any unresolved chronic toxicity with Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade >= 2, from previous anticancer therapy, except for alopeciaXx_NEWLINE_xXUnresolved toxicity ? Common Terminology Criteria for Adverse Events (CTCAE) grade 2 from previous anti-cancer therapy except alopecia (if applicable) unless agreed that the patient can be entered after discussion with the medical monitorXx_NEWLINE_xXPersistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy, excluding alopeciaXx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version [v]4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXAny unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade 1) from previous anti-cancer therapy, excluding alopecia. Subjects with irreversible toxicity greater than grade 1 that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy).Xx_NEWLINE_xXWith the exception of alopecia, any unresolved toxicities from prior therapy ? Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria For Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXPatients who have not recovered from adverse events attributed to prior anti-cancer therapy (i.e. have residual toxicities > grade 1, except for alopecia, neuropathy, lymphocytopenia and other non-clinically significant adverse events)Xx_NEWLINE_xXPersistent toxicities (>= Common Terminology Criteria for Adverse Events [CTCAE] grade 2), with the exception of alopecia, caused by previous cancer therapyXx_NEWLINE_xXHas gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade > 3 within 6 months of registrationXx_NEWLINE_xXResidual acute toxic effects of prior anti-cancer therapy that have not resolved to Common Terminology Criteria for Adverse Events version 4 (CTCAE v.4) grade =< 1 (except alopecia or other grade II or above toxicities not considered a safety risk for the patient at investigator's discretion)Xx_NEWLINE_xXUnresolved toxicities from prior anticancer therapy, defined as having resolved to Common Terminology Criteria for Adverse Events (CTCAE, version 4.03), grade 0 or 1, with the exception of alopeciaXx_NEWLINE_xXFully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1Xx_NEWLINE_xXAny unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade 2) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version [v]4.03), grade =< 2, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXIs still experiencing toxicity related to prior treatment and assessed as Common Terminology Criteria for Adverse Events (CTCAE) grade > 1. Exceptions are alopecia and/or anorexia. The eligibility of patients who are still experiencing irreversible toxicity that is not reasonably expected to be exacerbated by the study drugs in this study (eg, hearing loss) must be reviewed and approved by both the principal investigator and medical monitorXx_NEWLINE_xXHas not recovered from adverse events due to prior therapies, i.e. monoclonal antibody, chemotherapy, targeted small molecule therapy, radiation therapy, or surgery.\r\n* Note: Subjects with grade 2 neuropathy, alopecia and general disorders and administration site conditions (per Common Terminology Criteria for Adverse Events [CTCAE] version 4.0) are an exception to this criterion and may qualify for the study.Xx_NEWLINE_xXUnresolved toxicity from previous anticancer treatments, including investigational products (subjects must have recovered all unacceptable toxicity to ? Grade 1 Common Terminology Criteria for Adverse Events [CTCAE] toxicity). This does not extend to symptoms or findings that are attributable to the underlying diseaseXx_NEWLINE_xXAny unresolved toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade >= 2) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) less than or equal to grade 2 (except alopecia) at the time of screening however clinically relevant adverse events (AEs) that will impact on the adverse drug event (ADE) of the study drugs or safety of the subject must have resolved to grade 1 or betterXx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXPrevious treatment-associated toxicities resolved to Common Terminology Criteria for Adverse Events (CTCAE) grade =< 2 (except alopecia)Xx_NEWLINE_xXCommon Terminology Criteria for Adverse Events (CTCAE) version (v)4.0 grade 3-4 neuropathyXx_NEWLINE_xXAny unresolved toxicity >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 from previous anti-cancer therapy, except for alopecia and neurotoxicityXx_NEWLINE_xXProteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greaterXx_NEWLINE_xXAny unresolved toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or above) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXPresence of >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicity (except alopecia or peripheral neuropathy) due to prior cancer therapyXx_NEWLINE_xXPatients who received prior medical therapy for a NF1 related tumor must have recovered from the acute toxic effects of all prior therapy to =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5 before entering this studyXx_NEWLINE_xXAny unresolved Common Terminology Criteria for Adverse Events (CTCAE) grade >2 toxicity from previous anti-cancer therapy; patients with irreversible toxicity that is not reasonably expected to be exacerbated by study therapy (eg, hearing loss) may be enrolled after discussion with the principal investigatorsXx_NEWLINE_xXPeripheral neuropathy ? grade 2 (Common Terminology Criteria for Adverse Events CTCAE)Xx_NEWLINE_xXAny unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade 2) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)Xx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXPHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Persistent toxicities (>= Common Terminology Criteria for Adverse Events [CTCAE] grade 2) with the exception of alopecia and neuropathy, caused by previous cancer therapyXx_NEWLINE_xXPre-existing peripheral neuropathy > grade 1 (using Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.3 criteria)Xx_NEWLINE_xXAny unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathyXx_NEWLINE_xXBilirubin =< 1.5 times upper limit of normal (Common Terminology Criteria for Adverse Events [CTCAE] grade 1 baseline)Xx_NEWLINE_xXPatients must have recovered from all clinically relevant toxicities related to prior anticancer therapies to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03); exception to this criterion: patients with any grade of alopecia are allowed to enter the treatmentXx_NEWLINE_xXNeuropathy (sensory and motor) =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xXMust have =< grade 1 pre-existing peripheral neuropathy (as per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXUnresolved toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria, with the exception of alopeciaXx_NEWLINE_xXPre-existing motor or sensory neurotoxicity greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXPatients with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXPreexisting grade 3 or 4 nervous system disorder as per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03Xx_NEWLINE_xXAny unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade 2) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)Xx_NEWLINE_xXFailure to fully recover from acute, reversible effects defined as =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0 of prior chemotherapy regardless of interval since last treatment except alopecia and neuropathyXx_NEWLINE_xXGrade 3 or worse peripheral neuropathy as defined by Common Terminology Criteria for Adverse Events (CTCAE) v4.1Xx_NEWLINE_xXPatients must have recovered from toxicity related to prior therapy to at least grade 1 (defined by Common Terminology Criteria for Adverse Events version 4.0 [CTCAE 4.0]) or baseline level; chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis by the principal investigatorXx_NEWLINE_xXMust have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from the acute effects of any prior surgery, chemotherapy or radiation therapy; chronic residual toxicity (i.e. peripheral neuropathy) is permittedXx_NEWLINE_xXPersistence of any clinically relevant (Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or above) toxicities from previous AML therapyXx_NEWLINE_xXMust have recovered from adverse effects of any prior surgery, radiotherapy or other antineoplastic therapy; Common Terminology Criteria for Adverse Events (CTCAE) adverse events less than or equal to grade 1 are acceptable; CTCAE adverse events grade 2 or greater may be acceptable as determined by the principal investigatorXx_NEWLINE_xXAll previous therapies for cancer, including radiotherapy, major surgery and investigational therapies must be discontinued for >= 14 days (>= 28 days for mitomycin C or nitrosoureas) before cycle 1 day 1 (C1D1), and all acute effects of any prior therapy must have resolved to baseline severity or grade =< 1 Common Terminology Criteria for Adverse Events (CTCAE version [v] 4.03), except alopecia or parameters defined in this eligibility listXx_NEWLINE_xXUnresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 2 due to prior therapiesXx_NEWLINE_xXSymptomatic nodal disease, i.e. scrotal, penile or leg edema (>= Common Terminology Criteria for Adverse Events [CTCAE] grade 3)Xx_NEWLINE_xXAny unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade 2) from previous anti-cancer therapyXx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade =< 1Xx_NEWLINE_xXPHASE I: Persistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by prior cancer therapy, excluding alopeciaXx_NEWLINE_xXPHASE II: Persistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by prior cancer therapy, excluding alopeciaXx_NEWLINE_xXPatients eligible or ineligible for cisplatin-based chemotherapy. Cisplatin ineligibility is defined as meeting 1 of the following criteria: • Creatinine clearance (calculated or measured) <60 mL/min calculated by Cockcroft-Gault equation (using actual body weight) or by measured 24-hour urine collection for determination • Common Terminology Criteria for Adverse Events (CTCAE) Grade ?2 audiometric hearing loss • CTCAE Grade ?2 peripheral neuropathy • New York Heart Association ?Class III heart failure.Xx_NEWLINE_xXHave NO continuing acute toxic effects (except alopecia) of any prior chemotherapy, radiotherapy or surgical procedures; all such effects must have resolved to Common Terminology Criteria for Adverse Events (CTCAE, version 4.03) grade =< 1; surgery (except minor procedures such as biopsies, IV line placement, etc.) must have occurred at least 28 days prior to study enrollmentXx_NEWLINE_xXPatients must have recovered from all toxicities related to any prior anticancer therapies to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), provided that any concomitant medication is given prior to initiation of treatment with ceritinib; exception to this criterion: patients with any grade of alopecia are allowed to enter the treatmentXx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXRecovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 from toxicities related to any prior treatment, unless adverse events are clinically non-significant and/or stable on supportive therapyXx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 5.04 (CTCAE v5.04) grade =< 1 (except alopecia) at the time of enrollmentXx_NEWLINE_xXPeripheral neuropathy =< Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXAny unresolved chronic toxicity greater than Common Terminology Criteria for Adverse Event (CTCAE) grade 2 or greater from previous anti-cancer therapy (this criterion does not apply to alopecia)Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v4.0) grade 1 acceptableXx_NEWLINE_xXPulmonary hemorrhage/bleeding event > Common Terminology Criteria for Adverse Events (CTCAE) grade 2 within 4 weeks of first dose of study drugXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1,500/uL, equivalent to Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 grade 1Xx_NEWLINE_xXOther organ toxicity due to prior anticancer therapy (investigational agent, chemotherapy, or radiation therapy) except alopecia, and ototoxicity due to cisplatin not already covered in the inclusion/exclusion criteria, which has not recovered to Grade less than 2 per Common Terminology Criteria for Adverse Events (CTCAE) v4.0.Xx_NEWLINE_xXHas not recovered from adverse events due to prior therapies, i.e. monoclonal antibody, chemotherapy, targeted small molecule therapy, radiation therapy, or surgery; (Note: subjects with grade 2 neuropathy, alopecia and general disorders and administration site conditions [per Common Terminology Criteria for Adverse Events (CTCAE) version 4.0] are an exception to this criterion and may qualify for the study)Xx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXPatients must have been treated with fulvestrant for at least 56 days as their most current anti-cancer treatment, and they must be tolerating fulvestrant with at most grade I toxicity by Common Terminology Criteria for Adverse Events (CTCAE) v4.0Xx_NEWLINE_xXPre-existing peripheral neuropathy that is >= grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 criteriaXx_NEWLINE_xXContraindication to antiangiogenic agents, including:\r\n* Bronchopulmonary hemorrhage/bleeding event >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] v4.0) within 12 weeks prior to of initiation of treatment\r\n* Any other hemorrhage/bleeding event >= grade 3 (CTCAE v4.0) within 12 weeks prior to initiation of treatment\r\n* Serious non-healing wound, ulcer, or bone fractureXx_NEWLINE_xXExperiencing any clinically significant adverse events above grade 1 (according to Common Terminology Criteria for Adverse Events [CTCAE] 4.0) due to agents administered more than 30 days earlier; however, patients with grade 2 alopecia will be considered eligibleXx_NEWLINE_xXRecovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version 4 [v4])Xx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXPatients must have recovered from all toxicities related to prior anticancer therapies to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), provided that any concomitant medication is given prior to initiation of treatment with ceritinib; exception to this criterion: patients with any grade of alopecia are allowed to enter the treatmentXx_NEWLINE_xXPatients who have not recovered (=< Common Terminology Criteria for Adverse Events [CTCAE] grade 1) from adverse events (with the exception of alopecia) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) =< grade 1 (except alopecia) at the time of enrollmentXx_NEWLINE_xXHepatic toxicity grade 2 (using Common Terminology Criteria for Adverse Events [CTCAE] version 4 standard definitions)Xx_NEWLINE_xXAny unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) > grade 2 from previous anti-cancer therapyXx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grade =< 1 (except alopecia); grade 2 prior treatment related toxicities may be allowed after discussion with the principal investigatorXx_NEWLINE_xXChemotherapy, radiation, or biological cancer therapy within 4 weeks prior to the first dose of study drug, or who has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from the adverse events due to cancer therapeutics administered more than 4 weeks earlierXx_NEWLINE_xXThe subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan; the subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< Grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXBaseline hearing deficit (Common Terminology Criteria for Adverse Events [CTCAE] version 4.0 grade 2 or higher)Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4 (CTCAE v 4) grade =< 1 (except alopecia) at the time of enrollment; this requirement to return to =< grade 1 does not apply to immune checkpoint inhibitor related endocrinopathies (e.g. thyroiditis, hypophysitis, etc.) that necessitate hormone replacement therapy including, but not limited to levothyroxine, cortisol, and testosterone; CTCAE v5.0 will be utilized beginning April 1, 2018Xx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs) (e.g. albumin)Xx_NEWLINE_xXPatients with gastrointestinal bleeding or any other hemorrhage/bleeding event (Common Terminology Criteria for Adverse Events [CTCAE] version [v.]4) grade 3 or greater within 30 days prior to registration will be ineligibleXx_NEWLINE_xXResolution of all chemotherapy or radiation-related toxicities =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1 severity, except for alopecia and hematologic toxicity; patients taking temozolomide can start study treatment 23 days from the last temozolomide dose; for all other chemotherapy drugs, study treatment can start as long as adverse events related to their treatment is =< to grade 1Xx_NEWLINE_xXPatients with unresolved diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xXPatients must have recovered from all acute toxicities (defined as Common Terminology Criteria for Adverse Events [CTCAE] 4.0 =< grade 1) associated with any prior therapyXx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXPatients with =< grade 1 peripheral neuropathy are eligible for this trial using the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0, regardless of use of therapy for neuropathy including gabapentinXx_NEWLINE_xXHistory of infection meeting any of the following criteria:\r\n* Any infection that would be scored as grade 4 by Common Terminology Criteria for Adverse Events (CTCAE) that occurred within six weeks of study screening\r\n* Any infection that would be scored as grade 3 by CTCAE that occurred within two weeks of study screening\r\n* History of fungal and mycobacterial infections, unless at least six weeks has passed since the completion of induction antimicrobial therapy; patients may be receiving consolidation therapy for infections of these typesXx_NEWLINE_xXRecovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to =< grade 2 (Common Terminology Criteria for Adverse Events version 4 [CTCAE v4])Xx_NEWLINE_xXAt least one clinical symptom probably or definitely attributed to KSHV-MCD\r\n* Intermittent or persistent fever for at least 1 week (> 38 Celsius degree [C])\r\n* Fatigue (Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or greater)\r\n* Gastrointestinal symptoms (includes nausea and anorexia) (CTCAE grade 1 or greater)\r\n* Respiratory symptoms (includes cough and airway hyperreactivity) (CTCAE grade 1 or greater)Xx_NEWLINE_xXPulmonary hemorrhage/bleeding event >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 within 4 weeks of first dose of study drugXx_NEWLINE_xXParticipants with active diarrhea >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 despite medical managementXx_NEWLINE_xXAny unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2 platinum-therapy related neuropathyXx_NEWLINE_xXUnresolved toxicity > Common Terminology Criteria for Adverse Events (CTCAE) grade 2 from previous anti-cancer therapy, except for alopeciaXx_NEWLINE_xXPresence of CTCAE (Common Terminology Criteria for Adverse Events) grade ? 2 peripheral neuropathy.Xx_NEWLINE_xXPeripheral neuropathy of Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade >= 2Xx_NEWLINE_xXPatients who have been treated with most recent radiotherapy, hormonal therapy, immunotherapy, chemotherapy or investigational drugs within ?21 days or 5 half-lives (whichever is shorter) from enrolment (screening), and/or who have any unresolved NCI Common Terminology Criteria of Adverse Events (CTCAE) v4.03 > Grade 1 treatment-related side effect (with the exception of alopecia).Xx_NEWLINE_xXRecovered to Common Terminology Criteria for Adverse Events (CTCAE) grade < or equal to 2 from toxicities related to prior therapy within 4 weeks prior to start of any therapyXx_NEWLINE_xXInability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea e.g., Cohn's disease, malabsorption, or Common Terminology Criteria for Adverse Event (CTCAE) Grade > 2 diarrhea of any etiology at baselineXx_NEWLINE_xXCommon Terminology Criteria for Adverse Events (CTCAE) v4 Grade ?2 audiometric hearing lossXx_NEWLINE_xXPeripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 4.0. In CTCAE version 4.0 grade 2 sensory neuropathy is defined as “moderate symptoms; limiting instrumental activities of daily living (ADLs).Xx_NEWLINE_xXResolution of all acute toxic effects of prior therapy or surgical procedures to Common Terminology Criteria for Adverse Events (CTCAE) grade =< 1 (except alopecia)Xx_NEWLINE_xXPersistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy, excluding alopeciaXx_NEWLINE_xXActive, ongoing toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or higher) from prior therapyXx_NEWLINE_xXRENAL COHORT: Recovery to baseline or ? grade 1 Common Terminology Criteria for Adverse Events (CTCAE) v.4.0 from toxicities related to any prior treatments, unless adverse events (AEs) are clinically nonsignificant and/or stable on supportive therapyXx_NEWLINE_xXRecovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v.)4.0 from toxicities related to any prior treatments, unless AE(s) are clinically non-significant and/or stable on supportive therapyXx_NEWLINE_xXPatient who has had chemotherapy, radiation therapy, or biological cancer therapy within four weeks prior to the first dose of study drug, or who has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from the adverse events (AEs) due to cancer therapeutics administered more than four weeks earlierXx_NEWLINE_xXPatients must not be suitable for concurrent cisplatin as determined by the following:\r\n* Creatinine clearance less than 60ml/min; glomerular filtration rate (GFR) should be assessed by calculation from serum/plasma creatinine (Cockcroft-Gault formula)\r\n* Common Terminology Criteria for Adverse Events (CTCAE) grade (Gr) >= 2 hearing loss\r\n* CTCAE Gr >= 2 neuropathyXx_NEWLINE_xXFully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade 2 or less, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXPersistent toxicities (> Common Terminology Criteria for Adverse Events [CTCAE] grade 2) caused by previous cancer therapy, excluding alopecia.Xx_NEWLINE_xXAny unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or more from previous anti-cancer therapy, except alopecia, hearing loss, peripheral neuropathy or non-clinically significant laboratory abnormalitiesXx_NEWLINE_xXPatient has not recovered to CTCAE Common Terminology Criteria for Adverse Events (CTCAE) (version 4.03) grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy.Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) =< grade 1 (except alopecia)Xx_NEWLINE_xXAny unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade 1) from previous anti-cancer therapy with the exception of alopecia; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)Xx_NEWLINE_xXPre-existing peripheral neuropathy that is >= grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) v4 criteriaXx_NEWLINE_xXSensory peripheral neuropathy > Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xXHistory of Common Terminology Criteria for Adverse Events (CTCAE) grade >= 3 hypersensitivity to paclitaxel or Cremophor ELXx_NEWLINE_xXNervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [V] 4.0) resulting from prior therapy must be =< grade 2Xx_NEWLINE_xXAny acute toxicities due to prior chemotherapy and / or radiotherapy that have not resolved to a Common Terminology Criteria for Adverse Events version 4.0 grade <=1 with the exception of chemotherapy induced alopecia and grade 2 peripheral neuropathy.Xx_NEWLINE_xXPart 1 patients who have not recovered to < Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicities related to prior therapy are ineligibleXx_NEWLINE_xXParticipants with diarrhea >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from related toxicity to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXSubjects who have not recovered from toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia (grade 2 or 3 toxicities from prior antitumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as grade 2 chemotherapy-induced peripheral neuropathy, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor)Xx_NEWLINE_xXPatients with peripheral neuropathy >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 are ineligibleXx_NEWLINE_xXFailure to fully recover from acute, reversible effects defined as =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0 of prior chemotherapy regardless of interval since last treatmentXx_NEWLINE_xXGrade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events [CTCAE], version [v.] 4):Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade =< 1 (except alopecia) at the time of enrollmentXx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Common Terminology Criteria for Adverse Events [CTCAE] grade 1 or baseline, with the exception of alopecia)Xx_NEWLINE_xXActive, clinically serious infections > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXAny chemotherapy related toxicities from prior treatment (> grade 2 per Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.0)Xx_NEWLINE_xXSensory peripheral neuropathy =< grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] version [v.] 4.0)Xx_NEWLINE_xXCholesterol < Common Terminology Criteria for Adverse Events (CTCAE) grade 3Xx_NEWLINE_xXThe subject has recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicities related to prior treatment, except alopecia, lymphopenia, other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXRecovery from previous cancer treatment (=< grade 1 by Common Terminology Criteria for Adverse Events [CTCAE] 4.0 criteria) prior to first radiation treatmentXx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXPatients who have not recovered to < Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicities related to prior therapy are ineligibleXx_NEWLINE_xXDocumented hypercoagulable disorders or vasculopathies:\r\n* International normalized ratio (INR) value more than a grade 1 toxicity by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 criteria (> 1-1.5 x upper limit of normal [ULN]; > 1-1.5 times above baseline if on anticoagulation)\r\n* Activated partial thromboplastin time (APTT) value more than a grade 1 toxicity by CTCAE v 4.0 criteria (> ULN-1.5 x ULN)Xx_NEWLINE_xXPatients with pre-treatment peripheral neuropathy greater than grade 1 per the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 will be excludedXx_NEWLINE_xXSubjects who have a history or current evidence of bleeding disorder, i.e. any hemorrhage/bleeding event of Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 within 4 weeks before the start of study treatmentXx_NEWLINE_xXPatient has >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxietyXx_NEWLINE_xXSymptomatic peripheral neuropathy > grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) criteriaXx_NEWLINE_xXAny valve disease Common Terminology Criteria for Adverse Events (CTCAE) gradeXx_NEWLINE_xXPatients with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) (version 4.03) grade 2Xx_NEWLINE_xXThe corticosteroids prednisone and dexamethasone may be continued until the day before treatment start if all related adverse events are controlled at CTCAE version 4.03 grade =< 1Xx_NEWLINE_xXAll prior treatment- related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) =< grade 1 (except alopecia) at the time of enrollmentXx_NEWLINE_xXPrevious intolerance to BCG intravesical therapy suggested by development of systemic BCG infection in the past and/or grade 4 or greater adverse effect by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0Xx_NEWLINE_xXHave recovered from prior drug-related toxicity to grade =< 1 Common Terminology Criteria for Adverse Events version 4 (CTCAE v. 4), within 21 days of initiation of on-study treatmentXx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 grade =< 1 (except alopecia) at the time of registration; subjects with toxicities attributed to prior anti-cancer therapy which are not expected to resolve and result in long lasting sequelae are permitted to enrollXx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 grade =< 1 (except alopecia) at the time of randomizationXx_NEWLINE_xXCommon Terminology Criteria for Adverse Events (CTCAE) recovered to baseline or CTCAE =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXPrevious chemotherapy (adjuvant and metastatic regimens) and hormonal therapy allowed, but chemotherapy must have been discontinued at least 21 days prior to starting study treatment and hormonal therapy at least 7 days prior to starting study treatment; patients must have recovered from acute Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 grade >= 2 side effects of previous treatments; participants with alopecia G2 (CTCAE v4.0) will be allowed in the studyXx_NEWLINE_xXToxicities (> Common Terminology Criteria for Adverse Events [CTCAE] grade 2) caused by previous cancer therapyXx_NEWLINE_xXPrior systemic or antiangiogenic therapy for HCC (including thalidomide, sorafenib, sunitinib, or bevacizumab); prior systemic therapy for other diagnoses is permitted if greater than 6 months have elapsed since last dose, any prior toxicity has recovered to =< grade 1 by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0, and treatment was not discontinued for toxicityXx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1,500/mm^3, equivalent to CTEP Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, grade 1; this ANC cannot have been induced or supported by granulocyte colony stimulating factorsXx_NEWLINE_xXActive clinically serious infection > Common Toxicity Criteria for Adverse Events (CTCAE version 4.0 [v 4.0]) grade 2Xx_NEWLINE_xXPre-existing peripheral neuropathy, if present, must be < grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1,500/mm^3, equivalent to Common Toxicity Criteria for Adverse Events version (v)3.0 (CTCAE) grade 1Xx_NEWLINE_xXThe participant has resolution to Grade 1 or less by Common Terminology Criteria for Adverse Events Version 4.0, of all clinically significant toxic effects of previous therapy.Xx_NEWLINE_xXSubject has cardiac disorders (Common Terminology Criteria for Adverse Events [CTCAE] version 4.03 Grade 3 or 4).Xx_NEWLINE_xXPreexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events v4.0).Xx_NEWLINE_xXFor Cohort B: Has peripheral neuropathy Common Terminology Criteria for Adverse Events ?2 except due to traumaXx_NEWLINE_xXPeripheral neuropathy >= grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] version [v]4)Xx_NEWLINE_xXPatient must have a corrected QT (QTc) interval on electrocardiogram (ECG) =< 0.48 seconds by Bazett’s calculation (=< Common Terminology Criteria for Adverse Events [CTCAE] version [v.]4 grade 2) prior to randomizationXx_NEWLINE_xXPRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have received any chemotherapy, biologic agent, or any investigational agent within 14 days prior to registration. Patients must have recovered from any adverse events to Common Terminology Criteria for Adverse Events (CTCAE) grade 0-1 prior to registrationXx_NEWLINE_xXToxicities from previous cancer therapies must have recovered to grade 1 (defined by Common Terminology Criteria for Adverse Events [CTCAE] 4.0) Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basisXx_NEWLINE_xXNot recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia, oxaliplatin-related neuropathy, asymptomatic electrolyte abnormalities =< grade 2, and other non-clinically significant adverse eventsXx_NEWLINE_xXAll previous chemotherapy or radiation therapy-related toxicities, except dry mouth, dysphagia, esophagitis, mucositis, alopecia, and irreversible late sequelae of radiation therapy, must have resolved to Grade 0 or 1 per Common Terminology Criteria for Adverse Events (CTCAE v 4.03), and all wounds from prior surgery must have adequately recovered.Xx_NEWLINE_xXBilirubin greater than 1.5 x upper limit of normal (ULN) (Common Terminology Criteria for Adverse Events [CTCAE] v4.0 grade 1)Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xXNone of the following co-morbid conditions:\r\n* Cataracts of grade 2 or greater as per Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\r\n* Retinopathy of grade 2 or greater as per CTCAE version 4.0\r\n** Note: patients that have cataracts that do not require surgery are eligible\r\n** Note: serious adverse events will be reported on CTEP-Adverse Event Reporting System (AERS) using CTCAE version (v)5.0\r\n* Deep vein thrombosis/pulmonary embolism (DVT/PE) within the past 6 months\r\n** Note: patients that are on anticoagulant therapy for maintenance are eligible as long as the DVT and/or PE occurred > 6 months prior to enrollment, and there is no evidence for active thrombosis (either DVT or PE)Xx_NEWLINE_xXFailure to recover (to Common Terminology Criteria for Adverse Events [CTCAE] Grade 0 or Grade 1) from acute non hematologic toxicity (except all grades alopecia or Grade 2 or lower neuropathy ), due to previous therapy, prior to Screening.Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXActive Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade 3 or higher viral, bacterial, or fungal infectionXx_NEWLINE_xXSubject has unresolved clinically significant toxicities from prior anticancer therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher.Xx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXCTCAE (Common Terminology Criteria for Adverse Events) Grade ?2 bleeding disorder within 4 weeks before the start of anetumab ravtansineXx_NEWLINE_xXAll prior therapy related toxicities must have resolved to Grade less than 2 severity per Common Terminology Criteria for Adverse Events (CTCAE version 4.03), except alopecia and infertility.Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXHas history of gastrointestinal bleeding or any other hemorrhage/bleeding event >= grade 3 (Common Terminology Criteria for Adverse Events [CTCAE], version [v.] 4) within 30 days prior to entry in to the trialXx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) version (v)4, grade 2 not controlled with antibioticsXx_NEWLINE_xXPrevious chemotherapy, immunotherapy, or radiation therapy must have been completed at least 14 days prior to Step 2 Randomization and all toxicity must be resolved to Common Toxicity Criteria for Adverse Events (CTCAE) version (v) 4.0 grade 1 (with the exception of CTCAE v4.0 grade 2 neuropathy) prior to Step 2 RandomizationXx_NEWLINE_xXHas recovered from the toxic effects of prior therapy to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or to their clinical baselineXx_NEWLINE_xXPresence of peripheral neuropathy ? Common Terminology Criteria for Adverse Events (CTCAE) Grade 2Xx_NEWLINE_xXAll acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedures must have resolved to Common Terminology Criteria for Adverse Events (CTCAE, version 4.0) grade =< 1Xx_NEWLINE_xXSubjects who have not recovered from toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as less than Grade 2 severity per Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).Xx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXHistory of grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4) or greater acute intracranial hemorrhageXx_NEWLINE_xXNot recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and neuropathy; alopecia and neuropathy must have resolved to =< grade 2; congestive heart failure (CHF) must have been =< grade 1 in severity at the time of occurrence and must have resolved completely prior to registrationXx_NEWLINE_xXUnresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia (grade 2 or 3 toxicities from prior antitumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor)Xx_NEWLINE_xXSubject has not recovered from adverse reactions to prior cancer treatment or procedures (surgery, chemotherapy, immunotherapy, radiation therapy) to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or better.Xx_NEWLINE_xXPatient with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2; (CTCAE version 4.0)Xx_NEWLINE_xXWith the exception of alopecia, any unresolved toxicities from prior anti-tumor treatments (excluding corticosteroids) should be no greater than Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) grade 1 at the time of study entryXx_NEWLINE_xXPatient has >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxietyXx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXPrior treatment related side effects must have resolved to < grade 2 severity per Common Terminology Criteria for Adverse Events (CTCAE version 4.03), except alopecia and infertilityXx_NEWLINE_xXSubjects who have a history or current evidence of bleeding disorder, i.e. any hemorrhage / bleeding event of CTCAE (Common Terminology Criteria for Adverse Events) Grade ?2 within 4 weeks before the start of study Treatment.Xx_NEWLINE_xXNo proteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greaterXx_NEWLINE_xXPartcipant has not recovered from the acute toxic effects (Common Terminology Criteria for Adverse Events [CTCAE] grade ? 1) of prior anticancer therapy, radiation, or major surgery/significant trauma (except alopecia or other toxicities not considered a safety risk for the particiapants at the Investigator's discretion).Xx_NEWLINE_xXSignificant neuropathy per Common Terminology Criteria for Adverse Events (CTCAE) version (ver.) 4.03 or current version (grade 3 and above, or grade 2 with pain) within 14 days prior to enrollmentXx_NEWLINE_xXThe participant has uncontrolled hypertension, as defined in Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, prior to initiating study treatment, despite antihypertensive intervention.Xx_NEWLINE_xXPeripheral neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higherXx_NEWLINE_xXPatients must have recovered from clinically significant, acute, treatment-related toxicities of prior therapies; for those acute baseline adverse events attributable to prior therapy, recovery is defined as a toxicity grade =< 2, using Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0, unless otherwise specified in the inclusion and exclusion criteria\r\n* Agents that potentially fit into more than one category or do not clearly fit into any category listed above should be discussed with the study principal investigator (PI) prior to enrollmentXx_NEWLINE_xXRecovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 from toxicities related to any prior treatment, unless adverse events are clinically non-significant and/or stable on supportive therapyXx_NEWLINE_xXPeripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 4.0; in CTCAE version 4.0 grade 2 sensory neuropathy is defined as \moderate symptoms; limiting instrumental activities of daily living (ADLs)\Xx_NEWLINE_xXAny unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) >Grade 2 from previous anti-cancer therapyXx_NEWLINE_xXPrior therapy (chemotherapy, radiation therapy, and surgery) is allowed if completed at least 2 weeks prior to registration and if all treatment-related toxicities are resolved to =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1, with the exception of alopecia and hematologic values otherwise meeting the bone marrow function criteriaXx_NEWLINE_xXHas gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade > 3 within 6 months of start of study drugXx_NEWLINE_xXElectrocardiography (EKG) corrected QT (QTc) < 480 msec (Common Terminology Criteria for Adverse Events [CTCAE] grade 2)Xx_NEWLINE_xXPatient has >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxietyXx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 grade =< 1 (except alopecia) at the time of enrollmentXx_NEWLINE_xXPatients must have recovered from effects of recent surgery, radiotherapy, chemotherapy or biologic/targeted therapy to baseline or Common Terminology Criteria for Adverse Events (CTCAE) less than or equal to grade 1 (excluding alopecia or other non-clinically significant adverse events [AE's])Xx_NEWLINE_xXAll treatment related toxicities, except alopecia, must have recovered to Grade 1 or better (Common Terminology Criteria for Adverse Events (CTCAE); version 4.0) prior to administration of the first dose of study treatment.Xx_NEWLINE_xXWith the exception of alopecia, any unresolved toxicities from prior chemotherapy should be no greater than Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) grade 1 at the time of starting study treatmentXx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade =< 1 (except alopecia); Grade 2 prior treatment related toxicities may be allowed after discussion with the Principal InvestigatorXx_NEWLINE_xXUnresolved toxicities from any prior therapy greater than Common Terminology Criteria for Adverse Events Grade 1 at the time of starting study treatment with the exception of alopecia.Xx_NEWLINE_xXNeuropathy (sensory) =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xX? Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 thrombocytopenia, ORXx_NEWLINE_xXPatients with peripheral neuropathy > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXParticipants must have recovered from the acute toxic effects of prior therapy to a grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] v.4.0) level prior to enrollment (does not apply to alopecia)Xx_NEWLINE_xXParticipants with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 5 (CTCAE v5) grade =< 1 (except alopecia) at the time of enrollmentXx_NEWLINE_xXSubjects must have recovered from the acute toxicities of all prior therapy before entering this study; for those acute baseline adverse events attributable to prior therapy, recovery is defined as a toxicity grade =< 2, using Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0, unless otherwise specified in the inclusion and exclusion criteriaXx_NEWLINE_xXPersistent Common Toxicity Criteria for Adverse Effects (CTCAE v4.0) greater than or equal to grade 2 diarrhea regardless of etiology.Xx_NEWLINE_xXToxicities of prior therapy (excepting alopecia) should be resolved to =< grade 1 per the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0Xx_NEWLINE_xXPresence of any unresolved >=Grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] version 4.0) toxicity from previous anti-cancer therapy at the time of enrollment, except alopecia or Grade 2 anemia. Subjects with MM who have ?Grade 2 peripheral neuropathy (per CTCAE v4.0) are permitted.Xx_NEWLINE_xXSignificant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease, malabsorption, or Common Terminology Criteria for Adverse Events (CTCAE) grade > 2 diarrhea of any etiologyXx_NEWLINE_xXUnresolved toxicity from other agents. Patients with unresolved Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03 grade 3 or greater toxicity from prior administration of another investigational drug and/or anti-cancer treatment are not eligible.Xx_NEWLINE_xXPersistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy, excluding alopecia.Xx_NEWLINE_xXHas had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (prior to the first dose of study therapy, or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Gr 1 or better from any AEs that were due to cancer therapeutics administered more than 4 weeks earlierXx_NEWLINE_xXUnresolved clinically significant toxicities from prior anticancer therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) => Grade 2Xx_NEWLINE_xXAdequate pulmonary function, defined as ? Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 dyspnea and saturated oxygen (SaO2) ? 92% on room airXx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 5), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drugXx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drugXx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 5), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXUnresolved diarrhea >= Common Terminology Criteria for Adverse Events (CTCAE) version 4, grade 1Xx_NEWLINE_xXLast chemotherapy or treatment with another systemic anti-cancer agent must have stopped >= 4 weeks prior to enrollment (or >= 5 half-lives for oral tyrosine-kinase inhibitors or 2 weeks for palliative radiotherapy); participants must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] =< 1 or baseline) from acute toxicities of any previous therapy (with the exception of alopecia)Xx_NEWLINE_xXNervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4) resulting from prior therapy must be < grade 2Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) =< grade 1 (except alopecia) at the time of enrollmentXx_NEWLINE_xXGastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for adverse Events (CTCAE), v. 4 grade 3 or greater within 30 days prior to registrationXx_NEWLINE_xXPatients that have not recovered from adverse events related to prior chemotherapy, radiation therapy or multikinase inhibitors to Common Terminology Criteria for Adverse Events (CTCAE) 4.0 grade 1 or less except for alopeciaXx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies, including surgery, except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXHave a grade 2 or greater laboratory abnormalities (Common Terminology Criteria for Adverse Events version 4 [CTCAE v4]) at baseline for any of the following:\r\n* Hemoglobin\r\n* White blood cell count\r\n* Platelet count\r\n* Alanine transferase\r\n* Aspartate transferase\r\n* CreatinineXx_NEWLINE_xXUnresolved toxicities from prior systemic therapy that are Common Terminology Criteria in Adverse Events (CTCAE) version 3.0 or 4.0 >= grade 2 in severity except alopeciaXx_NEWLINE_xXPatients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ? CTCAE Grade 3 within 4 weeks of start of study medication (CTCAE: Common Terminology Criteria for Adverse Events).Xx_NEWLINE_xXPatients with =< grade 1 peripheral neuropathy are eligible for this trial using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0, regardless of use of therapy for neuropathy including gabapentinXx_NEWLINE_xXSubjects with baseline symptoms of fever and/or cough and/or shortness of breath and/or wheezing and/or fatigue grade >= 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.0)Xx_NEWLINE_xXThe participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXAny unresolved chronic toxicities > grade 2, measured by Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v4)Xx_NEWLINE_xXPatients must have recovered to =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 from toxicity of prior chemotherapy or biologic therapy and must not have had prior chemotherapy or biologic therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C, 8 weeks for 7-hydroxystaurosporine [UCN-01])Xx_NEWLINE_xXClinically significant peripheral neuropathy (defined as >= Common Terminology Criteria for Adverse Events [CTCAE] grade 2 [version 4.0]), neurosensory or neuromotor toxicity, regardless of causalityXx_NEWLINE_xXSubjects must be recovered from any toxicity related to prior anti?neoplastic therapy (to grade =< 1); patients with Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or less sensory neuropathy or any grade alopecia are eligibleXx_NEWLINE_xXPatients with active diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXPatients with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE version 4) grade 2 at the time of signing consentXx_NEWLINE_xXAny chemotherapy related toxicities from prior treatment (>= grade I per Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.0)Xx_NEWLINE_xXPatients with known grade 3 or higher (per Common Terminology Criteria for Adverse Events [CTCAE] version 4.0 [v.4.0] criteria) active systemic or cutaneous viral, bacterial, or fungal infectionXx_NEWLINE_xXPatients with gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for Adverse Events (CTCAE) grade >= 3 within 30 days prior to study entryXx_NEWLINE_xXPatients with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXPrior systemic chemotherapy for the study cancer (sarcoma); note that prior chemotherapy for a different cancer is allowable; however, unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor)Xx_NEWLINE_xXPersistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy, excluding alopecia;Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.0), grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXAny persistent, unresolved Common Terminology Criteria for Adverse Events (CTCAE) Grade ?2 drug-related toxicity (except alopecia, erectile impotence, tinnitus, hot flashes, and loss of libido) associated with previous treatment. Inclusion of patients with persistent neuropathy or hearing loss Grade ?2 due to previous treatment requires discussion with the sponsor.Xx_NEWLINE_xXHas not recovered (i.e., equivalent to a Common Terminology Criteria for Adverse Events [CTCAE] ?Grade 2) from the clinically significant toxic effects of prior anticancer therapy. Exception: subjects who have received treatment with a proteasome inhibitor such as bortezomib may have CTCAE Grade 2 neuropathy.Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 grade =< 1 (except alopecia) prior to the first dose of the study drugXx_NEWLINE_xXHas unresolved, clinically significant toxicities from prior anti-cancer therapy defined as > Grade 1 on Common Terminology Criteria for Adverse Events.Xx_NEWLINE_xXLack of recovery of prior cancer therapy-related adverse events to grade =< 1 (NCI Common Terminology Criteria for Adverse Events [CTCAE] v4.03; except alopecia); stable persistent grade 2 peripheral neuropathy may be allowed as determined on a case-by-case basis at the discretion of the principal investigator (PI); patients with platinum-related grade 2 or greater hypomagnesemia (on replacement) will be eligibleXx_NEWLINE_xXHas had chemotherapy, radiation, or biological cancer therapy within 4 weeks prior to the first dose of study therapy, or who has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from the adverse events due to cancer therapeutics administered more than 4 weeks earlierXx_NEWLINE_xXPatients with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXPatients who have not recovered (Common Terminology Criteria for Adverse Events [CTCAE] =< grade 1) from adverse events due to prior treatments, except for alopecia, or base stable grade 2 tinnitus (not interfering with activities of daily living [ADL]’s) or stable grade 2 sensory neuropathy without pain or motor component, and not interfering with ADL’sXx_NEWLINE_xXPatients must have completed surgical resection and adjuvant chemotherapy (adjuvant radiotherapy excluded) with no significant persisting treatment related toxicity (grade 1 toxicity per Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.0 allowed) as determined by the treating physicianXx_NEWLINE_xXHistory of severe (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03 grade 3 or higher) allergic reaction to a drug, vaccination, or biological preparationXx_NEWLINE_xXKnown unresolved toxicities due to prior anticancer therapy, defined as not having resolved to grade 0 or 1 (by Common Terminology Criteria for Adverse Events [CTCAE] version 4 criteria), unless otherwise defined in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXRecovery from acute toxicity of prior treatment for renal cell carcinoma (RCC) (to =< grade 1 the active version of Common Terminology Criteria for Adverse Events [CTCAE] or to a level permitted under other sections of inclusion/ exclusion criteria); additionally, in patients who have received standard or experimental treatments for their RCC at least approximately 5 half-lives should have elapsed from the last dose at the time of study entryXx_NEWLINE_xXOngoing or active infection of Common Terminology Criteria for Adverse Events (CTCAE) Grade ? 3Xx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1,500/ul, equivalent to Common Toxicity Criteria (Common Toxicity Criteria for Adverse Events [CTCAE] version [v.]4.0) grade 1Xx_NEWLINE_xXUnresolved toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), Grade 0 or 1, unless otherwise defined in the inclusion/exclusion criteria with the exception of alopecia.Xx_NEWLINE_xXFailure to recover to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 2 from clinically significant toxicities due to prior cancer therapies or to any investigational agentsXx_NEWLINE_xXPts who have grade III-IV elevations in liver transaminases (as defined by the Common Terminology Criteria for Adverse Events [CTCAE] version [v.] 4.0) or a bilirubin in excess of 1.5 mg/dlXx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXAll acute toxic effects of any previous radiotherapy, chemotherapy, or surgical procedures must have resolved to grade 1 or lower according to Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0)Xx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients have diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXPatients must not have >= grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/mcl, equivalent to Common Terminology Criteria (CTCAE version [v] 4.03) grade 1Xx_NEWLINE_xXPatients must have recovered from all toxicities related to prior anticancer therapies to grade =< 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03) provided that concomitant medication is given prior to initiation of treatment with LDK378 [ceritinib], except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study; additionally, patients with any grade of alopecia are allowed on treatmentXx_NEWLINE_xX< grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXExisting anticancer treatment-related toxicities of Grades >= 2 (except for alopecia and Grade 2 sensory neuropathy) according to Common Terminology Criteria for Adverse Events (CTCAE v4.03).Xx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelaeXx_NEWLINE_xXAll acute toxic effects of any previous radiotherapy, chemotherapy, or surgical procedures must have resolved to grade I or lower according to Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0)Xx_NEWLINE_xXPatients with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 1Xx_NEWLINE_xXAny unresolved chronic toxicity greater then Common Terminology Criteria (CTC) grade 2 from previous anticancer therapyXx_NEWLINE_xXActive clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXPresence of peripheral neuropathy ? Common Terminology Criteria for Adverse Events (CTCAE) Grade 2Xx_NEWLINE_xXPatients with pre-existing neuropathy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (motor or sensory)Xx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXAnxiety ? Common Terminology Criteria (CTC) of adverse events (AE) grade 3.Xx_NEWLINE_xXUnresolved toxicity of Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or greater from previous anti-cancer therapy or radiotherapyXx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (V) 5 grade =< 1 (except alopecia); certain exceptions apply, such as immunotherapy-induced hypothyroidism or adrenal insufficiency or panhypopituitarism requiring stable doses of hormone replacement or rash from prior therapyXx_NEWLINE_xXCentral nervous system function defined as:\r\n* Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlled\r\n* Nervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version 4 [v4]) resulting from prior therapy must be =< grade 2Xx_NEWLINE_xXUnresolved toxicity >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 from previous anti-cancer therapy except alopecia or long-term radiation toxicity (radiation related toxicity 3 months or greater after radiation exposure)Xx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])Xx_NEWLINE_xXPreexisting peripheral neuropathy of grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events v 4.0)Xx_NEWLINE_xXClinically significant non-hematologic toxicity after prior therapy has recovered to grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or newerXx_NEWLINE_xXSubject who has an ongoing toxicity ? Grade 2 (Common Terminology Criteria for Adverse Event [CTCAE] v4.03) attributable to prior medication to treat solid tumor (except alopecia) at the time of screening.Xx_NEWLINE_xXUnresolved non-hematologic toxicities from prior therapies that are > Common terminology Criteria for Adverse Events (CTCAE) Grade 1 (with the exception of alopecia [Grade 1 or 2 permitted])Xx_NEWLINE_xXResolution of all transplant-related toxicity to =< grade 2 per Common Terminology Criteria for Adverse Events (CTCAE) version (v.)4Xx_NEWLINE_xXPatients must not have grade 2 or greater pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE] 4.0)Xx_NEWLINE_xXPre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Criteria for Adverse Events (CTCAE) v4.0).Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXPatients may not have any baseline comorbidities or laboratory abnormalities which would be of grade 3 or worse if graded as toxicities by Common Terminology Criteria for Adverse Events (CTCAE) (excepting alopecia); an exception is also made for neurologic comorbidities (e.g. ataxia, aphasia) arising as a consequence of the brain tumor; symptoms severe enough to warrant medical treatment as is offered on this study are by definition grade 3Xx_NEWLINE_xXtoxicity attributed to previous anticancer therapy that did not resolve to Common Terminology Criteria for Adverse Events (CTCAE) grade =1Xx_NEWLINE_xXSkin rash Common Terminology Criteria for AEs (CTCAE) Grade greater than 1 from previous anti-EGFR therapy at time of randomizationXx_NEWLINE_xXAll prior anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed in the protocol) must be <=grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.0) at the time of randomization.Xx_NEWLINE_xXSubject has persistent nonhematological toxicities of >= Grade 2 (Common Terminology Criteria for Adverse Events v4), with symptoms and objective findings, from prior AML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery).Xx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 grade =< 1 (except alopecia) at the time of randomization and crossoverXx_NEWLINE_xXProteinuria by Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greaterXx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy per Common Terminology Criteria for Adverse Events (CTCAE)Xx_NEWLINE_xXRecovery to CTCAE (Common Terminology Criteria for Adverse Events Version 4.03) Grade 0 or Grade 1 or recovery to baseline preceding the prior treatment of any previous drug / procedure-related toxicity (except alopecia, anemia, and hypothyroidism)Xx_NEWLINE_xXActive infections of CTCAE (Common Terminology Criteria for Adverse Events Version 4.03) Grade >2 or infections of CTCAE Grade 2 not responding to therapyXx_NEWLINE_xXDocumented hypersensitivity (Common Terminology Criteria for Adverse Events [CTCAE] grade >= 2) to any drug containing polysorbate 80Xx_NEWLINE_xXAll prior anti-cancer treatment-related toxicities (except alopecia) must be <= Grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 at the time of enrollmentXx_NEWLINE_xXThe subject has unresolved clinically significant toxicities from prior anticancer therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher.Xx_NEWLINE_xXPeripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 4.0; in CTCAE version 4.0 grade 2 sensory neuropathy is defined as \moderate symptoms; limiting instrumental activities of daily living (ADLs)\Xx_NEWLINE_xXGrade 2 or worse edema within 14 days to study day 1, per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4Xx_NEWLINE_xXPatients with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXAny unresolved chronic toxicity with Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2, from previous anti-NF1 therapy, except for alopeciaXx_NEWLINE_xXMust have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version 4 or has returned to baseline; alopecia > grade 1 is permittedXx_NEWLINE_xXPatients with diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 2Xx_NEWLINE_xXSubjects who have not recovered from acute toxicities as a result of prior anti-cancer therapy to less than or equal to Grade 1, according to Common Terminology Criteria for Adverse Events (CTCAE), except for peripheral neuropathy (see Exclusion 6) and alopecia.Xx_NEWLINE_xXProteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher.Xx_NEWLINE_xXAll toxicities from prior therapies must have resolved to Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0 grade I or better by the time of study enrollmentXx_NEWLINE_xXPresence of peripheral edema > Grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version 4)Xx_NEWLINE_xXPulmonary hemorrhage/bleeding event >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 within 4 weeks of first dose of study drugXx_NEWLINE_xXPatients with diarrhea > Common Terminology Criteria for Adverse Events Version 4 (CTCAE V.4) grade 2Xx_NEWLINE_xXPresence of neuropathy > grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version 4.0) at baselineXx_NEWLINE_xXPatients who have not recovered (Common Toxicity Criteria [CTC] =< grade I) from adverse events due to prior treatmentsXx_NEWLINE_xXPulmonary hemorrhage/bleeding event >= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drugXx_NEWLINE_xXCurrent peripheral neuropathy greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 except due to traumaXx_NEWLINE_xXPatients must have recovered from acute toxicities resulting from therapy administered prior to entering this study to grade 1 or less (Common Terminology Criteria for Adverse Events [CTCAE] 4); alopecia may be unresolvedXx_NEWLINE_xXPatients must have =< grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE] v4.0)Xx_NEWLINE_xXSubject has an ongoing toxicity ? Grade 2 (Common Terminology Criteria for Adverse Event [CTCAE] v4.03) attributable to prior medication to treat solid tumor (except alopecia) at the time of screening.Xx_NEWLINE_xXPresence of >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicity (except alopecia) due to prior therapyXx_NEWLINE_xXAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade =< 1 (except for adverse events [AEs] not considered to be dose-limiting toxicities [DLTs] in this trial such as alopecia and lymphopenia) at the time of enrollment; if there are any questions, please contact the study's principal investigatorXx_NEWLINE_xXPatients must have recovered from all toxicities related to prior anticancer therapies to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03); exception to this criterion: patients with any grade of alopecia are allowed to enter the treatmentXx_NEWLINE_xXAny hemorrhage or bleeding event >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 within 4 weeks prior to start of study medicationXx_NEWLINE_xXPresence of >= grade 3 non-hematologic toxicity common terminology criteria (CTC) version 4 from the previous treatmentXx_NEWLINE_xXRecovered from adverse events (to grade 1 or less toxicity according to Common Terminology Criteria for Adverse Events [CTCAE] 4.0) due to agents administered previously; NOTE: chemotherapy-induced alopecia and grade 2 neuropathy are acceptableXx_NEWLINE_xXPatients with pre-existing peripheral neuropathy must have < grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] 4.0) at the time of registrationXx_NEWLINE_xXPatient has >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxietyXx_NEWLINE_xXNewly diagnosed clinical grade 2 or higher radiation pneumonitis according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteriaXx_NEWLINE_xXDiarrhea < grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) version 4Xx_NEWLINE_xXCommon Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher proteinuriaXx_NEWLINE_xXDepression >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.0)Xx_NEWLINE_xXHepatic or renal toxicity (glomerular filtration rate [GFR] < 30) greater than or equal to grade 2 (using Common Terminology Criteria for Adverse Events [CTCAE] version 4 standard definitions)Xx_NEWLINE_xXHave grade 1 or 2 symptomatic dry mouth (xerostomia) according to CTEP NCI Common Terminology Criteria for Adverse Events (CTCAE version 4.0)Xx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events 4.03 [CTCAE 4.03])Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXAll toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version 4) or baseline before administration of study drug; subjects with toxicities attributed to prior anti-cancer therapy and which are not expected to resolve and result in long lasting sequelae such as neuropathy after platinum-based therapy, are permitted to enrollXx_NEWLINE_xXPrior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade <=1 severity (Common Terminology Criteria for Adverse Events [CTCAE] v4.03, or later versions)Xx_NEWLINE_xXReporting grade 1 or greater of the following symptoms persistently for more than 2 weeks: neuropathic pain, allodynia, areflexia, dysesthesia, paresthesia, hyperesthesia, hypoesthesia or glove and stocking syndrome as defined by Common Terminology Criteria for Adverse Events (CTCAE version [v.] 4.03)Xx_NEWLINE_xXEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unresolved toxicities from prior anti cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaXx_NEWLINE_xXPresence of any toxicities attributed to prior anti-cancer therapy that are not resolved to grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version 4.0) or baseline before administration of study drugXx_NEWLINE_xXPotassium, < 4.0 mmol/L despite supplementation; or above the Common Terminology Criteria for Adverse Events (CTCAE) grade 1 upper limitXx_NEWLINE_xXNo clinically relevant deviations in renal function (serum creatinine > grade 2 Common Terminology Criteria for Adverse Events [CTCAE] version 4.0); maximal interval between confirmation of renal function and injection of 18F FSPG is 1 weekXx_NEWLINE_xXWith the exception of alopecia, any unresolved toxicities from prior anti-tumor treatments (excluding corticosteroids) should be no greater than Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) grade 1 at the time of study entryXx_NEWLINE_xXHas not recovered to Common Toxicity Criteria for Adverse Events Grade 1 or better from the adverse events due to cancer therapeutics administered more than 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXCLINICAL SYMPTOMS (EACH AT LEAST GRADE 1 BY COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS [CTCAE] DEFINITIONS)Xx_NEWLINE_xXParticipants must not have residual adverse events from previous therapy greater than Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) grade 2 at the time of registrationXx_NEWLINE_xXAll chemotherapy or radiation-related toxicities must have resolved to Grade <2 severity per Common Terminology Criteria for Adverse Events (CTCAE v4.03), except alopecia and infertility.Xx_NEWLINE_xX